Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Bibtex

@article{e156d60e17734815a6c5064fbf3b59bf,
title = "Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group",
abstract = "Mantle cell lymphoma (MCL) is considered incurable. Intensive immunochemotherapy with stem cell support has not been tested in large, prospective series. In the 2nd Nordic MCL trial, we treated 160 consecutive, untreated patients younger than 66 years in a phase 2 protocol with dose-intensified induction immunochemotherapy with rituximab (R) + cyclophosphamide, vincristine, doxorubicin, prednisone (maxi-CHOP), alternating with R + highdose cytarabine. Responders received highdose chemotherapy with BEAM or BEAC carmustine, etoposide, cytarabine, and melphalan/ cyclophosphamide) with R-in vivo purged autologous stem cell support. Overall and complete response was achieved in 96{\%} and 54{\%}, respectively. The 6-year overall, event-free, and progression-free survival were 70{\%}, 56{\%}, and 66{\%}, respectively, with no relapses occurring after 5 years. Multivariate analysis showed Ki-67 to be the sole independent predictor of event-free survival. The nonrelapse mortality was 5{\%}. The majority of stem cell products and patients assessed with polymerase chain reaction (PCR) after transplantation were negative. Compared with our historical control, the Nordic MCL- 1 trial, the event- free, overall, and progression- free survival, the duration of molecular remission, and the proportion of PCR- negative stem cell products were significantly increased (P < .001). Intensive immunochemotherapy with in vivo purged stem cell support can lead to long-term progression- free survival of MCL and perhaps cure. Registered at www. isrctn. org as # ISRCTN 87866680.",
author = "Geisler, {Christian H.} and Arne Kolstad and Anna Laurell and Andersen, {Niels S.} and Pedersen, {Lone B.} and Mats Jerkeman and Mikael Eriksson and Marie Nordstrom and Eva Kimby and Boesen, {Anne Marie} and Outi Kuittinen and Lauritzsen, {Grete F.} and Herman Nilsson-Ehle and Elisabeth Ralfkiaer and M{\aa}ns {\AA}kerman and Mats Ehinger and Christer Sundstrom and Ruth Langholm and Jan Delabie and Marja-Liisa Karjalainen-Lindsberg and Peter Brown and Erkki Elonen",
note = "The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Oncology, MV (013035000), Pathology, (Lund) (013030000)",
year = "2008",
doi = "10.1182/blood-2008-03-147025",
language = "English",
volume = "112",
pages = "2687--2693",
journal = "Blood",
issn = "1528-0020",
publisher = "American Society of Hematology",
number = "7",

}